Clinical Trials Logo

Immune System Diseases clinical trials

View clinical trials related to Immune System Diseases.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06286839 Completed - Clinical trials for Immune System Diseases

Study of Cannabidiol (CBD) in Healthy Volunteers

Start date: May 12, 2022
Phase: N/A
Study type: Interventional

This was a prospective, single-centre, open label, randomized, two-arm, parallel design study to evaluate the effect of four-weeks consumption of active study product on primary endpoint in healthy adults

NCT ID: NCT05918627 Completed - Clinical trials for Immune System Disorder (Healthy Volunteer)

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

Start date: September 21, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple doses of SLx-2119 in healthy male participants.

NCT ID: NCT05918614 Completed - Clinical trials for Immune System Disorder (Healthy Volunteer)

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Start date: March 28, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.

NCT ID: NCT05918588 Completed - Clinical trials for Immune System Disorder (Healthy Volunteer)

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

Start date: November 21, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.

NCT ID: NCT05806567 Completed - Clinical trials for Immune System Disorder (Healthy Volunteers)

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Start date: July 27, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and pharmacokinetics (PK) effect of belumosudil on the uridine diphosphate glucuronosyltransferase (UGT)1A1 (Part 1), P glycoprotein (P-gp) (Part 2) and breast cancer resistance protein (BCRP)/organic anion transporting polypeptide (OATP)1B1 (Part 3) inhibition in the fed state in healthy male subjects.

NCT ID: NCT05803356 Completed - Immunity Disorders Clinical Trials

Genetic and Immunologic Characterization of IEI

Start date: December 20, 2018
Phase:
Study type: Observational

Inborn Errors of Immunity (IEI) include clinically heterogeneous rare genetic diseases depending on mutations in about 300 different genes. Clinically, this group of diseases is characterized by the presence of infectious, inflammatory, autoimmune, and lymphoproliferative symptoms. Understanding the pathogenesis of these diseases can guide the implementation of targeted therapies and improve prognosis. In recent years, IEI have been described that do not necessarily present with repeated infectious symptoms but rather with autoimmune, lymphoproliferative, and autoinflammatory manifestations, or with forms of immunodeficiency with a spectrum of susceptibility to one or few infectious agents. In this case, simple laboratory tests are not sufficient to characterize the disease since no particular immunophenotypic changes are evident. To correct classify the patients and to improve knowledge on the pathogenesis of the diseases, complex immunologic-functional studies are required. These studies should be started prior to genetic analysis, with the aim of targeting and narrowing it down. Although the ever-decreasing costs of Next Generation Sequencing (NGS) methods make it convenient to analyse many genes or even the entire exome simultaneously, the analysis of the data resulting from NGS can be complex and provide results of uncertain interpretation. In these cases, immunologic-functional studies can clarify the real causal role of the identified genetic variants. The identification of genotype-phenotype correlation is crucial to establish new therapeutic targets for diseases orphan of specific etiological treatments. In vitro and in vivo disease models are key tools to test drugs repositioning, as was the case for Lapaquistat in the treatment of periodic fevers caused by de-regulation of the cholesterol metabolic pathway.

NCT ID: NCT05650502 Completed - Clinical trials for Immune System Disease

Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin

ISAMIMA
Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate the effects of SMC (Seasonal malaria chemoprevention) with Sulfadoxine-Pyrimethamine (SP) and Amodiaquine (AQ) on the evolution of anti-malarial immunity of children and their susceptibility to malarial infection. This is a cross-sectional study on children aged 6 to 59 months with/without SMC in two villages in northern Benin. Sociodemographic and clinical data as well as repeated blood samples will be collected from 440 children (before, during and after treatment). Samples will be analyzed using a Luminex assay to investigate antibody responses to MSP (merozoite surface protein) , Glurp (Glutamate-Rich Protein) and a panel of PfEMP1. qPCR (quantitative polymerase chain reaction) will be used to detect the prevalence of malaria at this period and parasites infecting children will be characterize during the follow up.

NCT ID: NCT05367986 Completed - Sepsis Clinical Trials

Electro-acupuncture at Zusanli, Qihai, and Guanyuan Acupoints Regulate Immune Function in Patients With Sepsis

EAIm-sepsis
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study was to investigate the biochemical and clinical effects of electro-acupuncture in patients with sepsis.

NCT ID: NCT05242718 Completed - Immunity Disorders Clinical Trials

Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants

Start date: January 10, 2021
Phase: N/A
Study type: Interventional

A Phase IV, open-label, adaptive, 4-arm, multi-dose, single-centre, exploratory trial to assess the immune diversity response to oral administration of licensed Natural Health Products, in healthy adults, 60-70 years of age.

NCT ID: NCT05234203 Completed - Aging Clinical Trials

The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age

Start date: March 25, 2022
Phase: N/A
Study type: Interventional

This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.